Alexandra Erdmann and Kaspar Rufibach (2023): simIDM: Simulating Clinical Trials with Endpoints Progression-Free Survival and Overall Survival using an Illness-Death Model
Kaspar Rufibach, Lynda Grinsted, Jiang Li, Hans-Jochen Weber, Cheng Zheng, Jiangxiu Zhou (2023+): Quantification of follow-up time in oncology clinical trials with a time-to-event endpoint: Asking the right questions
Kaspar Rufibach (2021): eventTrack: Event Prediction for Time-to-Event Endpoints
Regina Stegherr and Kaspar Rufibach (2020). SAVVY: estimation of AE probabilities.
Björn Bornkamp, Kaspar Rufibach, Jianchang Lin, Yi Liu, Devan Mehrotra, Satrajit Roychoudhury, Heinz Schmidli, Yue Shentu, Marcel Wolbers (2020): Principal Stratum Strategy: Potential Role in Drug Development
Kaspar Rufibach, Dominik Heinzmann, Annabelle Monnet (2019): Integrating Phase 2 into Phase 3 based on an Intermediate Endpoint While Accounting for a Cure Proportion - with an Application to the Design of a Clinical Trial in Acute Myeloid Leukemia
Elina Asikanius, Kaspar Rufibach, Jasmin Bahlo, Gabriele Bieska, Hans Ulrich Burger (2016). Comparison of design strategies for a three-arm clinical trial with time-to-event endpoint: power, time-to-analysis, and operational aspects. Biom. J., 58(6), 1295-1310.